What changed for Ovarian Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Ovarian Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 538 to 545 (+7)
- Late-stage (Phase 3) trials 45 to 46 (+1)
- Trials on record 3,308 to 3,348 (+40)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Ovarian Cancer in July 2026. Voxsanity tracks 2 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 94 trials tracked for Ovarian Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05715216 · results posted 8 July 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of two medicines — nivolumab and etigilimab — in people with a type of ovarian cancer called platinum-resistant clear cell ovarian cancer. This means the cancer had stopped responding to a common chemotherapy treatment containing platinum. A total of 23 people started the trial, and 19 completed it, with 4 not completing it for reasons not detailed here. The trial was measuring how many participants had their tumours shrink or disappear (called the objective response rate), how long any tumour shrinkage...
-
NCT06390995 · results posted 16 June 2026
According to the results reported on ClinicalTrials.gov, this trial tested an experimental treatment called TAK-853, given at a dose of 6 mg/kg, in people with cancer. The trial had two phases. Phase 1 — the safety lead-in phase — enrolled 3 participants, and all 3 completed that phase. Phase 2 enrolled 25 participants, none of whom had completed the study by the time results were submitted. The main focus of Phase 1 was to look at how participants responded to the treatment in terms of unwanted medical events (called adverse events), particularly in the first treatment cycle. The reported da...
-
NCT04729387 · results posted 4 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04729387) enrolled 358 people with cancer — 180 in the group receiving a combination of two medicines called alpelisib and olaparib, and 178 in a comparison group receiving one of two standard chemotherapy medicines (paclitaxel or pegylated liposomal doxorubicin, sometimes called PLD). The main thing the trial was measuring was "progression-free survival" — that is, how long participants went before their cancer showed signs of growing or spreading, or before they passed away. The reported data shows that, for the primary...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05041257 · results posted 9 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 79 participants, all of whom received at least one dose of the study drug, mirvetuximab soravtansine. The trial was a single-group study, meaning there was no comparison group — everyone received the same treatment. The main thing the trial set out to measure was the "objective response rate," which refers to the proportion of participants whose tumours shrank by a meaningful amount (either disappearing completely or reducing in size by at least 30%) based on standard imaging criteria. The reported data shows that 51...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04106492 · results posted 14 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04106492) tested an experimental treatment called SQ3370, which combines two components — SQL70 and SQP33 — that are injected directly into tumours. The trial involved people with solid tumours, including a type called soft tissue sarcoma (a cancer that forms in soft tissues like muscle or fat). A total of 54 participants took part across 15 groups, with each group receiving a different dose or dosing schedule. The trial was designed in two stages: an early phase to find a recommended dose, and a later phase to look at how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05370521 · results posted 9 October 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called tildacerfont in people with polycystic ovary syndrome (PCOS) who had elevated levels of a hormone called DHEAS, which is produced by the adrenal glands. A total of 27 people took part — 17 in the tildacerfont group and 10 in the placebo (dummy treatment) group. Of these, 16 and 9 respectively completed the trial, with one person in each group not finishing. The reported data shows that the main thing being measured was the change in DHEAS levels from the start of the trial to the end. In the tildacerfo...
-
NCT03660826 · results posted 23 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03660826) enrolled 288 people across seven treatment groups, with between 40 and 43 participants in each group. The trial was testing several different drug combinations — including cediranib maleate, olaparib, capivasertib, and durvalumab — used alone or together. The main thing researchers were tracking was **progression-free survival**: how long participants went before their disease got worse or they passed away. The reported data shows that the median progression-free survival (that is, the midpoint time before disea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02489903 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02489903) enrolled people with cancer who had already received prior treatment. A total of 118 people entered the screening phase in one part of the study, and a further 21 in a later part. Of those, 94 went on to receive a combination of RRx-001 (an experimental drug) plus a standard chemotherapy duo called a "platinum doublet," while 11 received RRx-001 combined with platinum chemotherapy followed by more RRx-001, and 2 received a treatment chosen by their doctor (the "investigator's choice" comparison group). The trial...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02601950 · results posted 11 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02601950) looked at a drug called tazemetostat across eight separate groups of participants, each with a different type of rare cancer — including rhabdoid tumours, synovial sarcoma, renal medullary carcinoma (RMC), epithelioid sarcoma (ES), chordoma, and other related tumour types. In total, 267 people took part across all groups. The trial was measuring things like how many participants' tumours shrank or disappeared (called the "objective response rate"), how long that response lasted, and how long participants went wit...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04406623 · results posted 30 January 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called SL-172154 in 27 people with cancer. Participants were split into five groups, each receiving a different dose of the drug — 0.1, 0.3, 1.0, 3.0, or 10.0 milligrams per kilogram of body weight. All 27 participants across the five groups completed the study. The trial was primarily looking at what side effects or reactions occurred at each dose level, and whether any dose caused a reaction serious enough to limit how high the dose could go (called a "dose-limiting toxicity"). It also looked a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03994653 · results posted 20 January 2025
According to the results reported on ClinicalTrials.gov, this trial — called CLOCS — enrolled 306 people who had been diagnosed with ovarian cancer (referred to as "Cases") and 657 people without ovarian cancer ("Controls"). The trial was looking at whether shopping purchase records, specifically how often people bought pain relief and indigestion medications, might differ between these two groups in the period leading up to a cancer diagnosis. The reported data shows three sets of measurements comparing the average number of relevant items purchased by each group. In the first measurement, t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02312245 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants across four treatment groups. Each group received a different chemotherapy drug — paclitaxel (3 participants), gemcitabine hydrochloride (1 participant), liposomal doxorubicin (0 participants), or topotecan hydrochloride (9 participants) — with the drug chosen based on testing done on a laboratory-grown tumour model (called an "avatar") derived from each patient's own cancer. No participants completed the study as planned; all 13 did not complete it. Results for Arm C (liposomal doxorubicin) were not r...
-
NCT03113487 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03113487) enrolled 29 participants, all of whom received a combination of two treatments: p53MVA (a type of vaccine designed to target a protein called p53, which is often abnormal in cancer cells) and Pembrolizumab (an immunotherapy drug). Twenty-eight of the 29 participants completed the study. The trial was primarily measuring how many participants' tumours shrank or disappeared in response to the combination treatment, and also tracked how long participants lived without their cancer getting worse, how long they surviv...
-
NCT02601937 · results posted 3 October 2024
According to the results reported on ClinicalTrials.gov, this trial tested a medicine called tazemetostat in children and young people with cancer. The trial ran in two parts: a dose-escalation phase, where researchers gradually increased the dose across seven groups to find a safe starting dose for future studies (a total of 46 participants), and a dose-expansion phase, where four further groups — totalling 63 participants — received the medicine at set doses to look at how tumours responded. In all, 109 participants took part across the eleven groups. The reported data shows that in the dos...
-
NCT04672460 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04672460) enrolled a total of 73 participants across two groups (35 in one sequence and 38 in the other). The trial ran across several phases and was designed to compare how the body absorbs a drug called talazoparib when taken as two different capsule forms — an existing commercial capsule and a newer soft gel capsule — and to look at whether taking the soft gel capsule with food (fed) versus without food (fasted) made a difference. The trial measured levels of talazoparib in participants' blood over time. The reported d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03493464 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03493464) enrolled 14 participants in a single treatment group, and 13 of them completed the study (one did not complete it). The trial was measuring two main things: how well an imaging agent called BR55 showed up on ultrasound scans of participants, and how many participants experienced any unwanted health events (known as adverse events) after receiving the agent. The reported data shows that, of the participants whose scans were assessed, 5 showed no detectable imaging signal from BR55, 6 showed a weak signal that was...
-
NCT04296890 · results posted 7 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 people, all of whom received a drug called mirvetuximab soravtansine. The trial was measuring how the drug performed in participants with a specific type of ovarian cancer. The main thing researchers were tracking was the "objective response rate" — that is, the proportion of participants whose tumours shrank or disappeared by a defined amount during treatment. A number of secondary measures were also tracked, including how long any tumour shrinkage lasted, how long before the disease progressed, and how long part...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04209855 · results posted 1 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04209855) enrolled 453 people with ovarian cancer — 227 assigned to receive a drug called mirvetuximab soravtansine and 226 assigned to receive a chemotherapy chosen by their doctor (referred to as "Investigator's Choice" chemotherapy). The trial's main goal was to measure **progression-free survival** — that is, how long participants went without their disease getting worse or dying. Secondary goals included looking at overall survival (how long participants lived), how many people's tumours shrank, how long those respons...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04408599 · results posted 25 July 2024
According to the results reported on ClinicalTrials.gov, this trial tested a drug called NC410 in 46 people with solid tumour cancers. Participants were divided into seven groups, each receiving a different dose of NC410 — ranging from 3 mg up to 200 mg — to help researchers understand how the drug behaved at different dose levels. The trial was primarily looking at how many participants experienced side effects or unwanted health events during treatment (called "treatment-emergent adverse events"). It also tracked measures related to how participants' tumours responded to the treatment. The...
-
NCT02157974 · results posted 4 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 92 participants across five groups: 24 people without polycystic ovary syndrome (PCOS) who acted as a comparison group (controls), and 68 people with PCOS split into four sub-groups based on their medication status — those on no medication (42 people), those on no medication but also receiving a drug called Byetta (10 people), those taking the oral contraceptive pill (10 people), and those taking Metformin (6 people). Three participants in the medication-naive PCOS group did not complete the study; all others finished...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02326064 · results posted 15 March 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 221 women who had been found to have an ovarian tumour (a growth on the ovary). Of these, 209 women had a tumour that was classed as benign (non-cancerous), and 12 had a tumour classed as borderline or malignant (potentially or actively cancerous). All 221 women who started the trial also completed it. The trial was measuring two substances found in the blood — called CA125 and HE4 — which are sometimes referred to as "tumour markers." The study looked at the levels of these markers across the two groups of women. Th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03151005 · results posted 4 December 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03151005) enrolled 70 participants in total, split evenly into two groups of 35 — one group received a combination of metformin and a GLP-1 receptor agonist (a type of medication that affects blood sugar and appetite), and the other received a combination of metformin and an oral contraceptive pill. The trial was measuring several things related to reproductive hormones, body weight, liver function, and blood pressure. Of the 70 people who started, 60 completed the study — 30 in each group — and 5 people in each group did...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04034927 · results posted 13 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04034927) enrolled 61 people in total — 30 in a group receiving olaparib alone, and 31 in a group receiving olaparib combined with tremelimumab. The trial was looking at two main things: how many participants experienced their cancer growing or spreading (called "progression") or died during the study period, and how many people in the combination group were unable to complete at least three rounds of treatment due to serious treatment-related side effects (called dose-limiting toxicities, or DLTs). It also tracked a numbe...
-
NCT02734004 · results posted 13 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02734004) enrolled a total of 262 participants across seven groups, covering four cancer types: small cell lung cancer, breast cancer, ovarian cancer, and gastric cancer. The trial was run in two stages. In the first stage, the main thing being measured was how many participants had their disease controlled (meaning it had either shrunk or stayed stable) at 12 weeks into treatment. In the second stage, the focus shifted to ovarian cancer specifically, looking at how many participants showed a measurable response to treatme...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02101775 · results posted 8 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 124 people in total with recurrent, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Participants were split into three groups: 65 people received the experimental drug AZD1775 (a WEE1 inhibitor) combined with the chemotherapy drug gemcitabine; 34 people received a placebo combined with gemcitabine; and 25 people took part in a separate exploratory group also receiving AZD1775 with gemcitabine. The trial was primarily measuring how long people went without their cancer growing or spreading (ca...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03302156 · results posted 9 August 2023
According to the results reported on ClinicalTrials.gov, this trial looked at whether a special type of imaging scan — called a PSMA PET/MR scan — could accurately detect ovarian cancer. The scan uses a radioactive tracer to highlight a protein called PSMA, which can appear on some cancer cells. A total of 15 people started the trial across two groups: 2 healthy volunteers and 13 cancer patients (with 1 patient not completing the study, leaving 12 in the final analysis). A third planned group — a dosimetry group, which would have measured radiation exposure in more detail — had no participants...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03330405 · results posted 12 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03330405) tested a combination of two medicines — avelumab and talazoparib — across several groups of people with different types of advanced cancer, including lung cancer, breast cancer, ovarian cancer, bladder cancer, and prostate cancer. A total of 223 people took part across all groups: 12 in an early safety-testing phase (Phase 1b) and 211 across the later Phase 2 groups. The trial was measuring, among other things, how often tumours shrank or disappeared (called an "objective response"), and what kinds of unwanted me...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03642132 · results posted 6 April 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 79 participants across three treatment groups. The first group (32 people) received chemotherapy combined with a drug called avelumab, then moved on to avelumab plus talazoparib. The second group (13 people) received chemotherapy alone, then talazoparib on its own. The third group (34 people) received chemotherapy combined with bevacizumab, then continued on bevacizumab. The trial was measuring, among other things, how many participants experienced unwanted medical events (called adverse events) during treatment, how...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00849667 · results posted 30 December 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled around 1,100 people in total across three groups. Approximately 370 people received a lower dose of the study drug farletuzumab (1.25 mg/kg) combined with standard chemotherapy (taxane and carboplatin), around 366 received a higher dose of farletuzumab (2.5 mg/kg) with the same chemotherapy, and roughly 364 received a dummy (placebo) treatment alongside the same chemotherapy. The trial's main goal was to measure how long it took for participants' cancer to grow or spread again — known as "progression-free survival" —...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03382574 · results posted 14 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03382574) involved two groups of participants: one group received the drug denosumab followed by a risk-reducing surgical procedure to remove the fallopian tubes and ovaries, while the other group had the same surgery without the drug. The trial was designed to measure changes in cell activity in the fallopian tubes, ovaries, and uterine lining — specifically looking at a marker called Ki67, which indicates how quickly cells are dividing, as well as a range of other biological markers in tissue and blood samples. The repo...
See all 94 reported results for Ovarian Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, ovarian cancer currently attracts a very large amount of public research funding from the United States government, and that investment has remained broadly steady over recent years. This level of sustained attention suggests that ovarian cancer is considered a meaningful priority within the global research community. For patients, this broadly means that scientific...
See the full Ovarian Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.